Altimmune, Inc. (ALT) vs Crescent Biopharma, Inc. (CBIO)
A side-by-side comparison of Altimmune, Inc. and Crescent Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.70HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
CBIO
Crescent Biopharma, Inc.
$14.78HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — ALT vs CBIO
growth of $100 · dividends reinvested · last 9yALT -98.0% (-35.2%/yr)CBIO -96.5% (-31.1%/yr)CBIO compounded faster over this window
ALT CBIO
ALT vs CBIO: by the numbers
- •CBIO is the larger company ($549M vs $525M market cap).
- •Both run net losses; CBIO's is the smaller (-1371.51% vs -296000.00% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | CBIO |
|---|---|---|
| P/S ratio | 16938.06 | 46.20 |
| P/B ratio | 1.11 | 3.45 |
Profitability
| Metric | ALT | CBIO |
|---|---|---|
| Gross margin | 100.00% | 100.00% |
| Operating margin | -230460.98% | -1407.52% |
| Net margin | -296000.00% | -1371.51% |
| ROE | -19.35% | -99.83% |
| ROIC | -19.47% | -102.59% |
Growth (annualized)
| Metric | ALT | CBIO |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 39.89% |
| Total return CAGR (5Y) | -25.30% | -24.40% |
Frequently asked
- Which has grown faster, ALT or CBIO?
- Over the past five years, CBIO grew revenue faster — ALT at a -65.38% CAGR versus CBIO at 39.89%.
- How have ALT and CBIO total returns compared?
- Over the past 5 years, ALT delivered -25.30% and CBIO delivered -24.40% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Altimmune ROECrescent Biopharma ROEAltimmune operating marginCrescent Biopharma operating marginAltimmune revenue growthCrescent Biopharma revenue growthAltimmune free cash flowCrescent Biopharma free cash flow
Altimmune & Crescent Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.